IMMUNOTHERAPY

This phase II trial is testing whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with early-stage cervical cancer (stages IB1-IB3). About 50 participants will receive the combination, then undergo conservative su…

This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…

This study tests if adding a common heart medication (propranolol) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a certain type of colon cancer. About 45 adults with stage II or III colon cancer that is mismatch repair proficient (…

This study tests whether giving the immunotherapy drug atezolizumab before liver surgery can strengthen the body's immune response against liver cancer (hepatocellular carcinoma). About 30 patients will receive two doses before their operation. Researchers hope this approach migh…

This study tests giving an immunotherapy drug (pembrolizumab) before surgery to people with a specific type of colon cancer (dMMR). The goal is to see if the drug can shrink or eliminate the tumor so some patients may avoid surgery and instead be closely monitored. About 152 adul…

This trial is testing whether giving a special type of radiation (ultra-hypofractionated) along with immunotherapy before surgery is safe and feasible for people with retroperitoneal sarcoma. The study will enroll 28 participants. The main goal is to see how many patients have co…

This study tests two immunotherapy drugs (iparomlimab and tuvonralimab) in 30 women with a specific type of endometrial cancer that is mismatch repair-deficient. The goal is to see if the treatment can make the cancer disappear or shrink enough to avoid surgery. Participants must…

This phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal i…

This phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do …

This study tests whether adding a special type of radiation (quad shot radiotherapy) to a new immunotherapy drug (QL1706) plus chemotherapy can better control advanced non-small cell lung cancer. About 104 people with stage IV lung cancer that has not been treated yet will take p…

This study is for people with advanced biliary tract cancer whose disease is stable after initial chemotherapy plus immunotherapy. It compares four different maintenance treatments: immunotherapy alone or combined with lenvatinib, venadaparib, or interleukin-2. The goal is to fin…

This study is testing whether adding a probiotic called Lactobacillus johnsonii to standard chemotherapy and immunotherapy can help control advanced lung, breast, or stomach cancers. About 156 adults aged 18-75 will be randomly assigned to receive either the probiotic or a placeb…

This phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…

This study tests whether a digital tool combining weekly symptom surveys and a Fitbit can help monitor patients during immunotherapy for advanced melanoma. Forty participants will be randomly assigned to use the tool or receive usual care. The goal is to see if the system is easy…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…